TNF-alpha Inhibitors in Dermatology: Adalimumab, Infliximab, Etanercept
TNF-alpha inhibitors, including Adalimumab, Infliximab, and Etanercept, are pivotal in the management of various dermatological conditions, particularly psoriasis and hidradenitis suppurativa. These biologic agents target tumor necrosis factor-alpha (TNF-alpha), a key cytokine in inflammatory pathways, leading to significant improvement in disease symptoms and quality of life for patients.
Topics: TNF inhibitors, biologics, psoriasis
Overview / Definition TNF-alpha inhibitors are a class of biologic medications that specifically target and inhibit the action of tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in systemic inflammation. They are primarily used to treat chronic inflammatory skin conditions such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. Epidemiology The prevalence of conditions treated with TNF-alpha inhibitors varies significantly by population and condition: Psoriasis affects approximately 2-3% of the general population. Hidradenitis suppurativa has a prevalence of about 1%, with higher rates in females. Other indications like atopic dermatitis are increasingly recognized, especially in pediatric populations. Pathophysiology / Mechanism TNF-alpha plays a crucial role in the inflammatory cascade, promoting the activation of various immune cells and the production of other inflammatory mediators. In chronic inflammatory skin diseases: In psoriasis, TNF-alpha contributes to keratinocyte proliferation and inflammation. In hidradenitis suppurativa, TNF-alpha is implicated in the dysregulation of follicular epithelium and inflammation. TNF-alpha inhibitors work by binding to TNF-alpha, preventing it from interacting with its receptors, thereby reducing inflammation and altering the course of the disease. Clinical Presentation Patients eligible for TNF-alpha inhibitors typically present with: Moderate to severe psoriasis characterized by well-defined erythematous plaques covered with silvery scales. Hidradenitis suppurativa, presenting as painful nodules, abscesses, and sinus tracts in intertriginous areas. Atopic dermatitis with severe, persistent inflammation unresponsive to topical therapies. Diagnosis / Workup The diagnosis of conditions treated with TNF-alpha inhibitors is primarily clinical, supported by: Patient history, including the duration and severity of symptoms. Physical examination to assess the extent of skin involvement.